AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05821556 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Capecitabine
Description: The treatment should be started within 3 days from randomization. One cycle consisted of 28 days of treatment for both arms. Patients will continue to receive study treatment up to 6 cycles until disease progression, unacceptable toxicity, physician's decision, patient's refusal, or any other discontinuation criteria. Continuation of treatment, over the six cycles, will be allowed only in case of clinical benefit, defined as continuous decrease of CA19-9 concentration or radiological response, without unacceptable toxicity.~All subjects who finish treatment, whichever the reason, will enter in the follow-up. We expect that for the primary endpoint, PFS, follow-up will last up to 10 months after enrollment.~Anyhow, all subjects will be followed until death and data on subsequent treatment will be collected.
Study NCT05082168 — intervention group
Intervention type: DEVICE
Intervention: Capnodynamic monitoring
Description: In patients fully synchronized with mechanical ventilation, the capnodynamic method calculates the effective pulmonary blood flow, the end-expiratory lung volume and estimates the mixed venous oxygen saturation. The capnodynamic method uses short inspiratory or expiratory pauses to induce small changes in CO2 concentration the enable the mole balance to be resolved for the capnodynamic equation:~ELV x \[(FACO2(n)-FACO2(n-1)\] = delta(n) x EPBF \[CvCO2(n)\] - VTCO2.
Study NCT04578171 — intervention group
Intervention type: DRUG
Intervention: Mepolizumab
Description: 100 mg subcutaneous injections every four weeks
Study NCT05218200 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: deep breathing and coughing exercises with triflo
Description: patients will be given triflo. A video of the application of deep breathing and coughing exercises with triflo prepared by the researchers will be prepared. The video will be sent to the patients' phones. It will be ensured that the patients do the exercises every hour by watching the video and they will be followed.
Study NCT06291766 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: FreeStyle Libre 2, continous glucose monitoring
Description: The use of FreeStyle Libre 3 sensors and Libre Link app and Glooko app for analysing glucose control in pregnancy
Study NCT04428385 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Testing incentive
Description: A small incentive will be paid to the provider each time they perform a malaria rapid diagnostic test.
Study NCT04428385 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Conditional artemisinin combination therapy subsidy
Description: An additional discount on WHO-approved quality assured ACTs will be offered to individuals with a positive RDT.
Study NCT04767113 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Heparin sodium
Description: For infants without thrombosis at enrollment, heparin 1 U/kg/h/line for term infants was used and 0.5 U/kg/h/line for preterm infants. The speed of infusion was 0.5ml/h.~For infants with thrombosis at enrollment, heparin 10-15 U/kg/h for term infants was used with a target activated partial thromboplastin time 60-70s. Other interventions were at the clinical team's discretion under the local protocol.
Study NCT04767113 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: For infants enrolled, normal saline was infused at the corresponding speed.
Study NCT06499194 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: DASH diet
Description: The Dietary Approaches to Stop Hypertension (DASH) diets rich in fruits and vegetables and reduced in saturated fat can lower the risk for high blood pressure and assist with blood pressure control in hypertensive persons
Study NCT06499194 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: DASH diet
Description: The Dietary Approaches to Stop Hypertension (DASH) diets rich in fruits and vegetables and reduced in saturated fat can lower the risk for high blood pressure and assist with blood pressure control in hypertensive persons
Study NCT05558319 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bortezomib
Description: Bortezomib
Study NCT05558319 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: Bortezomib
Study NCT05558319 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Isatuximab
Description: Isatuximab
Study NCT05558319 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isatuximab
Description: Isatuximab
Study NCT05914870 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Multi-component training
Description: The multicomponent training group will perform 60 minutes of training per session:~* 10 minutes of joint mobility exercises and dynamic stretching.~* 20 minutes of strength work with 2 exercises; the first, bench press, at an intensity of 50% of your 1RM. The number of repetitions will be individualised for each subject by testing the loss of speed in the series with respect to the first repetition (15% loss); the second, the squat, at an intensity of 60% of your 1RM. The number of repetitions shall be individualised for each subject by means of the loss of speed test in the series with respect to the first repetition (10% loss). The rest between sets will be 3 minutes.~* 20 minutes of continuous cardiovascular work. The intensity will be increased every 4 weeks, from week 1 to 4 between 55%-65%FCR or VO2peak, from week 5 to 8 between 65%-%75%FCR or VO2peak and from week 9 to 12 between 75%-%85%FCR or VO2peak.~* 10 minutes of cool down and static stretching.
Study NCT05914870 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Continuous Cardiovascular Training
Description: The Continuous Cardiovascular Training group will perform 60 minutes of training per session distributed as follows:~Preparatory Phase: 10 minutes of standardised warm-up with joint mobility exercises and dynamic stretching.~Main Training Phase:~In this phase we will work 40 minutes of continuous aerobic exercise, maintaining the same intensity range throughout the session. We will increase the intensity every 4 weeks, from 1 to 4 you will work between 55%-65%FCR or VO2peak, from 5 to 8 between 65%-%75%FCR or VO2peak and from 9 to 12 between 75%-%85%FCR or VO2peak.~Post-training phase: 10' cool down and static stretching.
Study NCT05558319 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Iberdomide
Description: Iberdomide
Study NCT05558319 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lenalidomide
Description: Lenalidomide
Study NCT05558319 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Lenalidomide
Study NCT05558319 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: Dexamethasone
Study NCT05558319 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Dexamethasone
Study NCT04996966 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: human umbilical cord-derived mesenchymal stem cells
Description: In the MSCs injection group, 1×10\^6/kg human umbilical cord-derived mesenchymal stem cells were intravenously injected to the patient immediately after the surgery and at day 3 after the surgery.
Study NCT04996966 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: saline
Description: In the control group, saline containing 2% albumin (2ml/kg) were intravenously injected to the patient immediately after the surgery and at day 3 after the surgery.
Study NCT05090202 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: hbA1C
Description: hbA1C will be measured for all patients and results will be analysed into Non diabetic, Prediabetic and Diabetic
Study NCT05821387 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lucid-21-302
Description: A small molecule inhibitor of hypercitrullination
Study NCT05821387 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Product containing excipients with no active ingredients
Study NCT04717258 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fire and Rescue Service Safe and Well Visit
Description: Safe and Well Visits by the Fire and Rescue Service to prevent falls and improve quality of life in an older population
Study NCT04717258 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Self-Determination Theory informed trial invitation letter
Description: Invitation letter to take part in the FIREFLI study informed by Self-Determination Theory
Study NCT04717258 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pen included with reminder questionaire
Description: A pen will be included with the four-month reminder questionnaire.
Study NCT06108518 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Carvedilol
Description: Treatment group will take carvedilol 12.5mg once a day for 2 days; this is increased to 25 mg once a day or 12.5 mg twice a day for 3 months.
Study NCT06108518 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carvedilol
Description: Treatment group will take carvedilol 12.5mg once a day for 2 days; this is increased to 25 mg once a day or 12.5 mg twice a day for 3 months.
Study NCT06363643 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ELECTROSTIMULATION (ES)
Description: ES will receive the electrostimulator directly at home and will do three weekly Tele supervised sessions of 30 minutes of indirect electrostimulation. The treatment will last 4 weeks.
Study NCT06363643 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: EXERCISE (C)
Description: C will perform three weekly Tele supervised sessions of exercise. The treatment will last 4 weeks.
Study NCT04546633 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KAF156
Description: Provided as 50 mg or 100 mg tablets, to be taken QD 2 or 3 Days in combination with LUM-SDF, dose is based on body weight
Study NCT04546633 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LUM-SDF
Description: Provided as 60 mg, 120 mg or 240 mg powder in sachet, to be taken QD 2 or 3 Days in combination with KAF156, dose is based on body weight
Study NCT04546633 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Coartem
Description: Coartem® (dispersible tablets in blister pack) (for Cohorts 1 and 2), dose is based on body weight
Study NCT05399199 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: virtual reality distraction
Description: study group patients will view VR scene for 6 minutes before puncture .It involves a soothing nature experience and calming background music. Patients in intervention group will not able to see the puncture procedure due to the VR glasses.
Study NCT05340335 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remimazolam
Description: A beginning dose of remimazolam is 1mg/kg/hr. When sedation is not achieved in 10 minutes, the dose will be increased by 0.1mg/kg/hr in the next patient. When sedation is successful, the same dose will be used with the probability of 0.89, or the dose will be decreased by 0.1mg/kg/hr with the probability of 0.11 in the next patient. (maximal dose: 2mg/kg/hr)
Study NCT05682417 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Body Map Assessment Tool: MOVE Tool
Description: In VR, a spherical object approaches with linear trajectory the body of patients, it can be sent to 4 parts of the body (mid-arm/waist/hip/mid-thigh) both left and right side. Several conditions are presented, either the trajectory leads the object to touch the body, or it passes at ≠ distances from it. Patient is instructed to move only if he thinks the object will touch his body.~Procedure begins with a measurement taken on 3 body locations via the Move tool (shoulders/hips/thighs) to create an avatar allowing the tool to determine whether or not movement was necessary. Then, the movement of the patient is recorded. For each object/body distance, the software determines if dodging was necessary. The overestimation of the body schema corresponds to the average distance from which the patient considers that the object would have touched her body and performs a dodging movement, compared to her real morphological dimensions. This generates a body limit distortion % for each body area.
Study NCT04997096 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: 16-week, virtually supervised, technology-based, aerobic and resistance exercise program performed 3 days per week which starts at least 4 weeks after surgery
Study NCT04997096 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Attention Control
Description: Home-based stretching program consisting of one set of 4 static stretching exercises held for 30 seconds and performed 3 days/week. Participants will be shown how to use the booklet and instructed on how to complete the stretching exercises by an exercise trainer.
Study NCT05682417 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PAQ questionnaire
Description: This questionnaire has been translated and validated (French version, Luminet et al., 2021). This is a self-reported measure of alexithymia in 24 items. It is designed to measure all the components of alexithymia for both negative and positive emotions. Five subscale scores and six composite scores can be obtained from the questionnaire, with high scores indicating higher levels of alexithymia.
Study NCT05682417 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: F-DFlex questionnaire
Description: This questionnaire (Detail and Flexibility Questionnaire, French version of Maria et al, 2020) assesses cognitive rigidity. This questionnaire assesses two frequently impaired cognitive dimensions in people with anorexia nervosa, central coherence and cognitive flexibility in daily functioning using 20 self-completed items.
Study NCT05682417 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: BSQ questionnaire
Description: The Body Shape Questionnaire (BSQ, translated and validated in French by Rousseau et al., 2005) is a one-dimensional Anglo-Saxon self-questionnaire of 34 items that assesses concerns about body shape over the past four weeks. Responses are scored on a 6-point Likert scale. A score of 1 (never) means the problem is not present, up to a score of 6 (always) which means the problem is always present. The higher the score, the more the concern/dissatisfaction with one's body tends to be pathological.
Study NCT05682417 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Silhouette testing
Description: Body overestimation is assessed by the computerized silhouette test (adapted from Gardner \& Brown, 2010, Van der Linder et al., 2017). Twenty-seven Body Mass Index silhouettes ranging from 11 to 40 are presented to participants in random order. For each silhouette presented, the participant answers whether or not the silhouette presented corresponds to her current silhouette. A body underestimation index is calculated as follows: Estimated figure average BMI - actual BMI.
Study NCT05682417 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Eating Disorder Inventory - 2
Description: Allows self-assessment of symptoms of eating disorders. It is composed of 91 questions grouped into 11 subscales that assess specific cognitive and behavioral dimensions: desire for thinness, bulimia, body dissatisfaction, feeling of inefficiency, perfectionism, interpersonal distrust, interoceptive sensitivity, fears relating to maturity, asceticism. , impulsiveness and social insecurity. For each item, participants can answer always, usually, often, sometimes, rarely or never. The score for each item is between 0 and 3. The subscale scores are calculated by simply adding all the item scores for each specific subscale. This questionnaire has demonstrated good internal consistency, test-retest reliability, and validity (Garner, 1991)
Study NCT05682417 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: EDEQ questionnaire
Description: Or Eating Disorders Examination - Questionnaire (Fairburn \& Beglin, 2008). This questionnaire assesses eating behaviors and concerns about weight and body shape, using 28 items focusing on these aspects over the past 28 days.
Study NCT05682417 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: STAI questionnaire
Description: The Spielberger Anxiety Scale (STAI) State and Trait. This questionnaire includes two distinct scales: one evaluating the current state of anxiety (STAI form Y-A: feelings of apprehension, tension, nervousness and worry that the subject feels at a precise precise moment) and the second evaluating the anxious personality trait (STAI form Y-B: feelings of apprehension, tension, nervousness, and worry that the subject usually feels). The Y version was developed in order to eliminate the items having appeal to depression compared to the initial form. Each scale has 20 items. This questionnaire has good psychometric qualities regarding validity, reproducibility and inter-individual sensitivity. It correlates well with other anxiety questionnaires in a literature review of anxiety questionnaires (Elwood, 2012).
Study NCT05682417 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: BECK questionnaire
Description: Beck Depression Inventory (Beck, 1987). The inventory is composed of items related to depressive symptoms as well as physical symptoms. This is a questionnaire that gives a quantitative estimate of the intensity of depression. Investigators will use the abbreviated version consisting of 13 items, each item comprising 4 sentences corresponding to 4 degrees of increasing intensity of a symptom on a scale of 0 to 3. The total score corresponds to the sum of the different items and makes it possible to judge the presence of depression and its intensity.
Study NCT06303258 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Core Stabalization Exercises
Description: Low Intensity Warm Up Exercises Core Stabilization Exercises Cool Down Stretching Exercises
Study NCT06303258 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Generalized Antenatal Exercises
Description: Low Intensity WarmUp Exercise Aerobic Training Endurance Training Pelvic Floor Muscle Training Cool Down Stretching Exercises
Study NCT04553562 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Acupuncture
Description: Sterile adhesive pads will be placed after skin disinfection on the acupoints. Guanyuan (CV4)，Qihai (CV6)，bilateral Sanyinjiao (SP6), Yinbao (LR9), Qixue (KI13) and Fujie (SP14) will be inserted through the pads by the needles (0.30mm in diameter, 40 mm in length, Hwato Brand, Suzhou Medical Appliance Factory, China) to a depth of 25-30mm. Yintang (GV4) will be inserted through the pads by the needle (0.30mm in diameter, 25mm in length, Hwato Brand, Suzhou Medical Appliance Factory, China) to a depth of 10-15mm. The needles at all points will be lightly lifting, thrusting, and twirling every 10 minutes during each session with the sensation of sourness, achiness, heaviness and numbness (deqi). The participants will be treated three times a week, on alternate days (ideally), for 6 successive weeks; 18 sessions for each patient in total.
Study NCT04553562 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham acupuncture
Description: Sterile adhesive pads will be placed after skin disinfection on the acupoints. Needles (0.30 mm in diameter, 25 mm in length) with a blunt tip will be inserted at the Guanyuan (CV4)，Qihai (CV6)，bilateral Sanyinjiao (SP6), Yinbao (LR9), Qixue (KI13) and Fujie (SP14) without penetrating the skin. The participants will be treated three times a week, on alternate days (ideally), for 6 successive weeks; 18 sessions for each patient in total.
Study NCT05397197 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Electroencephalography
Description: experimental task, neuropsychological evaluation, clinical exam
Study NCT05238636 — intervention group
Intervention type: PROCEDURE
Intervention: Anti-reflux surgery - Stretta procedure or LINX device or laparoscopic fundoplication
Description: This is an observational study. Patients will choose which anti-reflux procedure (Stretta, LINX or fundoplication) they undergo with their clinician, as is standard practice, after which they will be offered recruitment to this study, which will perform investigations to assess for changes in physiology and symptoms.
Study NCT02052986 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: VASCAZEN
Description: All enrolled subjects will receive 4 capsules daily of VASCAZEN which delivers 3.0 grams of EPA and DHA
Study NCT05719194 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard SBT
Description: Weaning strategy in accordance with the care practices of the department, regarding the assessment of weaning criteria, SBT and extubation modalities.
Study NCT05719194 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SBT with T-piece or PSV
Description: - Risk factors of WIPO~Step 1 : Daily assessment of weaning criteria in accordance with the study protocol.~Step 2 : Spontaneous breathing trial with T-piece for an hour. Measure of protein and haemoglobin by blood sample before and after the trial.~Step 3 : Reconnect the patient to the ventilator for at least 30 minutes and then extubate if SBT is successful.~If SBT failed : no extubation and new SBT the next day. Optimization of cardiac function or fluid overload will be in charge of the investigator.~- No risk factors of WIPO~Step 1 : Daily assessment of weaning criteria in accordance with the study protocol.~Step 2 : Spontaneous breathing trial with pressure support ventilation (pressure support from 5 to 8 cmH20 - PEEP at 0 cmH20) for an hour.~Step 3 : Reconnect the patient to the ventilator for at least 30 minutes and then extubate if SBT is successful.
Study NCT05291624 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: AAGL Endometriosis Classification score - ULTRASOUND
Description: At baseline, ultrasonographic evaluation of patients by following AAGL Endometriosis Classification
Study NCT05291624 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: AAGL Endometriosis Classification score - SURGERY
Description: Within 1 month from enrollment, surgical evaluation of patients by following AAGL Endometriosis Classification
Study NCT05670743 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 38% silver diamine fluoride
Description: Topical application of 38% silver diamine fluoride to dental caries lesions